Method for preparing palbociclib and related intermediates

By optimizing the quinoline synthesis route of Pabocini, using 2,4-dichloropyrimidine as the starting material, the preparation of Pabocini is optimized through multiple-step reactions, and the low product yield and production cost in the prior art are solved. The high problem has achieved simplification and economic improvement of the synthetic route.

CN116283969BActive Publication Date: 2024-11-19HANGZHOU XINXI TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310159770.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-24
Publication Date
2024-11-19
Estimated Expiration
2043-02-24

AI Technical Summary

Technical Problem

The existing Pabosini synthesis route has problems such as low product yield, long synthesis route and high production costs, and is urgently needed to optimize.

Method used

Using 2,4-dichloropyrimidine as the starting material, the papocinib intermediate is prepared by cyclopentylamine amination and quinoline synthesis reaction, including cyclopentylamine pyrimidine, β-ethylketone acetate, and Bromine reaction, isopropyl magnesium chloride catalysis, platinum catalyst and hydrolysis protection steps under acidic conditions optimize the synthesis route, improve the reaction yield and simplify post-treatment.

Benefits of technology

The synthesis route is shortened, the reaction is mild, the post-treatment is simple, the reaction yield is high, and the production cost is low, which significantly improves the preparation efficiency and economicality of Pabosinib.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004093712520000021
    Figure BDA0004093712520000021
  • Figure BDA0004093712520000022
    Figure BDA0004093712520000022
  • Figure BDA0004093712520000023
    Figure BDA0004093712520000023
Patent Text Reader

Abstract

The present disclosure provides a method for preparing Palbociclib, which comprises the following steps: using 2,4-dichloropyrimidine as a starting material, introducing a cyclopentylamine group through cyclopentylamine amination to obtain 2-chloro-4-cyclopentylaminopyrimidine; 2-chloro-4-cyclopentylaminopyrimidine and β-acetoacetate react at 180 degrees Celsius and acidic conditions to obtain 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidine-7-one. The method disclosed in the present disclosure has the advantages of short synthetic route, mild reaction, simple post-processing, high reaction yield, low production cost, etc.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to methods for preparing palbociclib and its related intermediates. Background Art

[0002] Palbociclib is the world's first cyclin dependent kinase (CDK) 4 / 6 inhibitor developed by Pfizer in the United States. On February 3, 2015, the FDA accelerated the approval of Palbociclib for the treatment of ER+ / HER2- postmenopausal advanced breast cancer. Palbociclib can double the progression-free survival of breast cancer compared to letrozole, and is a new hope for breast cancer patients, with a breakthrough in efficacy.

[0003] In the prior art, there are a variety of routes for synthesizing Palbociclib, such as:

[0004] The preparation method of palbociclib in CN201410691233.0;

[0005] A method for preparing a palbociclib intermediate in CN201610320997.8;

[0006] A simple preparation method of palbociclib in CN201810014847.3.

[0007] However, these routes still have the disadvantages of low product yield and long synthetic route, and urgently need to be optimized. Summary of the invention

[0008] In order to solve the above problems, the present disclosure provides a new method for synthesizing palbociclib and related intermediates thereof, which has the advantages of short synthesis route, mild reaction, simple post-treatment, high reaction yield and low production cost.

[0009] Specifically, the first aspect of the present disclosure provides a method for preparing a palbociclib intermediate, comprising the following steps:

[0010] Using 2,4-dichloropyrimidine as a starting material, a cyclopentylamine group is introduced through amination with cyclopentylamine to obtain 2-chloro-4-cyclopentylaminopyrimidine;

[0011]

[0012] 2-Chloro-4-cyclopentylaminopyrimidine reacts with β-ethylketoacetate at 180 degrees Celsius under acidic conditions to give 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one.

[0013]

[0014] The method for preparing the palbociclib intermediate further comprises the following steps:

[0015] The 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one is subjected to a bromination reaction to obtain an intermediate A.

[0016]

[0017] The method for preparing the palbociclib intermediate further comprises the following steps:

[0018] Intermediate B 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester is reacted with intermediate A in the presence of isopropylmagnesium chloride to prepare intermediate C.

[0019]

[0020] The method for preparing the palbociclib intermediate further comprises the following steps:

[0021] Intermediate C is reacted with butyl vinyl ether in the presence of a platinum catalyst to obtain intermediate D.

[0022]

[0023] The method for preparing the palbociclib intermediate further comprises the following steps:

[0024] The intermediate D is hydrolyzed and deprotected under acidic conditions to obtain palbociclib

[0025]

[0026] The acidic conditions were obtained by adding 98% concentrated sulfuric acid.

[0027] The acidic condition is obtained by adding 98% concentrated sulfuric acid and benzothiazole ionic liquid.

[0028] The benzothiazole ionic liquid is selected from one or more of benzothiazole hydrogen sulfate, benzothiazole perchlorate, benzothiazole nitrate, and 3-(3-sulfonic acid)propylbenzothiazole dihydrogen phosphate hydrogen sulfate.

[0029] The mass ratio of the 98% concentrated sulfuric acid to the benzothiazole ionic liquid is 1:0.1-0.3.

[0030] The second aspect of the present disclosure provides palbociclib prepared by the method described in the first aspect.

[0031] The present invention adopts a special quinoline synthesis reaction, so that the synthesis starting compound of palbociclib is 2,4-dichloropyrimidine, and has a short synthesis route, mild reaction, simple post-treatment, high reaction yield and low production cost.

[0032] The above and other features, aspects and advantages of the present application will be more readily understood with reference to the following detailed description. Specific implementation plan

[0033] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present disclosure belongs. In the event of a conflict, the definitions in this specification shall prevail.

[0034] Unless otherwise indicated, all percentages, parts, ratios, etc. are by weight.

[0035] As used herein, the terms "comprises," "comprising," "having," "having," "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that includes a list of elements is not necessarily limited to only those elements but may also include other elements not expressly listed or inherent to the composition, process, method, article, or apparatus.

[0036] When quantity, weight portion or other numerical value or parameter are given with scope, preferred range or a series of upper preferred value and lower preferred value, it should be understood that it specifically discloses all ranges formed by any pair of numerical values ​​of any larger range limit or preferred value and any smaller range limit or preferred value, and no matter whether scope is disclosed respectively. For example, when describing the scope of "1 to 5", described scope should be understood as including the scope of "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5" etc. Unless otherwise stated, in the description of numerical range herein, described scope is intended to include range end value and all integers and fractions in the range.

[0037] In addition, the indefinite articles "a" and "an" before the elements or components of the present disclosure are intended to indicate that the number of occurrences (i.e., occurrences) of the elements or components is not limited. Therefore, "a" or "an" should be understood to include one or at least one, unless it is clearly indicated that the number is singular, otherwise the elements or components in the singular form also include the plural case.

[0038] Unless specifically stated, the materials, methods, and examples described herein are illustrative only and not limiting. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are still described herein.

[0039] The present disclosure is described in detail below.

[0040] Example

[0041] raw material:

[0042] The following raw materials were purchased from Sinopharm Chemical Reagent Co., Ltd. and dried.

[0043] Example 1

[0044] In a reaction vessel, add 3000 mL of pure ethanol, then add 2,4-dichloropyrimidine (1.0 equivalent). Add triethylamine (1.0 equivalent), then slowly add cyclopentylamine (1.2 equivalent) over 2 hours to control mild exotherm. After the addition of cyclopentylamine is complete, crystallize and dry to obtain 2-chloro-4-cyclopentylaminopyrimidine (yield 83%).

[0045]

[0046] 2-Chloro-4-cyclopentylaminopyrimidine (1.0 equivalent), N-methylpyrrolidine (50 mL), and triethylamine were added to a reaction vessel at room temperature, followed by β-ketoacetate (1.5 equivalent) and 98% sulfuric acid (5 ml). The mixture was heated to 180°C, reacted for 2 hours, cooled to room temperature, and H2O (100 mL, 10 vol) was added to precipitate 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one. After washing and drying with an isopropanol / water mixture (weight ratio 1:1), 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (yield 76%) was obtained.

[0047]

[0048] Acetonitrile (65 mL, 7.0 vol), N-bromosuccinimide (9.67 g, 1.5 equiv) and oxalic acid (0.65 g, 0.2 equiv) were added to 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (1.0 equiv). Heat to 60±5°C. Stir the reaction at 60°C for at least 6 hours, cool to 20°C and add distilled water (9 mL, 1 vol). After washing, filtering and drying, intermediate A (yield 88%) was obtained.

[0049] 1H NMR (500MHz, DMSO-d6): δ

[0050] 9.20(s,1H),5.82(m,1H),2.65(s,3H),2.11(m,2H),2.04(m,2H),1.86(m,2H),1.64(m,2H); 13C NMR (125MHz, DMSO-d6): δ

[0051] 158.2,158.2,157.6,154.1,144.0,120.9,113.0,54.4,28.3,25.7,18.3.

[0052]

[0053] Preparation of intermediate C

[0054] In the autoclave, intermediate B (63.4 g, 1.3 eq) was added and the mixture was kept at 20° C. for 30 minutes to dissolve the starting material. Isopropylmagnesium chloride (1.1 eq. in THF volume) was added dropwise to the reactor over 30 minutes and maintained at 20° C. for 40 minutes. The reactor was charged once with intermediate A (60.1 g, 0.1755 mole, 1 eq.) and rinsed with THF (50 mL rinse). Isopropylmagnesium chloride (93.9 g, 0.193 mol, 1.1 eq., 2nd charge (2.0 M in THF, 1.1 eq.) was added dropwise over 30 minutes. The batch was kept at 20°C for 90 minutes and then heated from 20°C to 60°C. After the reaction, a mixture of THF (2.86 vol) and HOAc (1 eq.) was added to quench the reaction. Then, the crystals precipitated and were filtered, washed, and dried to give Intermediate C in 92% yield.

[0055] 1H NMR (600MHz, THF-d8): δ

[0056] 9.36(s,1H),8.87(s,1H),8.22(d,J=8.8Hz,1H),8.04(d,J=2.9Hz,1H),7.39(dd,J=8.8,2.9Hz,1H),6.10(m,1H 13C NMR(150MHz,THF-d8):δ

[0057] 159.5,158.9,157.7,156.0,155.0,147.2,144.62,144.56,138.0,126.7,117.6,114.2,108.4,79.9,55.5,50.6,44.7,29.0,28.7,26.9,18.1.

[0058]

[0059] Preparation of intermediate D

[0060] The reaction kettle was charged with 1-butanol (60 mL, 6 mL / g), Intermediate C (10 g, 0.017 mole) and butyl vinyl ether (5.1 g, 0.051 mole, 3.0 equiv). Diisopropylethylamine (5.3 g, 0.041 mole, 2.4 equiv) was added and the mixture was sparged using nitrogen through a sparge tube for 30 minutes. Palladium acetate (0.16 g, 0.00068 mole, 0.0400 equiv) and bis(2-diphenylphosphinophenyl)ether (0.45 g, 0.00082 mole, 0.04800 equiv) were added. The mixture was heated to 95° C. during 30 minutes and the batch was stirred at 95° C. for 2 hours. The mixture was cooled to 80° C. and samples were taken to monitor the completion of the reaction. After completion, water (15 mL, 1.5 mL / g) and 1-butanol (30 mL, 3 mL / g) were added.

[0061] The solution was filtered through a 0.45 micron filter to remove the precipitated palladium. Water (35 mL, 3.5 mL / g) was added, followed by 1,2-diaminopropane (6.3 g, 0.085 mole, 5.0 equivalents). The mixture was stirred at 70°C for at least 30 minutes. Agitation was stopped and the mixture was allowed to settle for 15 minutes. The bottom aqueous phase was separated and the mixture was cooled to 60°C over a period of 30 minutes. Intermediate D was obtained after crystallization, washing and drying. The yield was 77%.

[0062] 1H NMR (600MHz, DMSO-d6): δ

[0063] 10.0(s,1H),8.87(s,1H),8.07(d,J=2.9Hz,1H),7.91(d,J=9.0Hz,1H),7.48(dd,J=9.0,2.9Hz,1H),5 .83(m,1H),4.47(d,J=1.6Hz,1H),4.05(d,J=1.6Hz,1H),3.77(t,J=6.4Hz,2H),3.48(width,4H),3.11(width,

[0064] 4H),2.37(s,3H),2.22(m,2H),1.89(m,2H),1.75(m,2H),1.61(m,2H),1.58(m,2H ), 1.43 (s, 9H), 1.38 (m, 2H), 0.90 (t, J = 7.39Hz, 3H); 13CNMR (150MHz, DMSO-d6): δ

[0065] 160.9,158.2,157.3,155.2,154.6,153.7,145.0,143.0,142.6,136.0,125.8,125.5,114.6,106.6,87.8,78.9,66.8,52.8,48.5,43.4,42.5,30.3,28.0,27.4,25.1,18.8,14.4,13.6.

[0066]

[0067] In a four-necked flask, add 240 g of 10% hydrogen chloride acetonitrile solution, add 0.1 mol of intermediate D, stir and react at 35-40 ° C for 5 hours, cool to 5-10 ° C after the reaction, filter, add the filter cake to 350 g of ice water, adjust the pH value to 6-7 with 5% sodium carbonate aqueous solution, filter, wash the filter cake with isopropanol, and dry under vacuum to obtain palbociclib (yield 95%).

[0068] 1H NMR (600MHz, DMSO-d6 / TFA): δ

[0069] 10.41 (s, 0.75H), 9.03 (s, 0.25H), 8.98 (s, 2H), 8.12 (d, J = 3.0 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.63 (dd, J = 9.1, 3.0 Hz, 1H), 5.84 (m, 1H), 3.40 (broad, 4H), 3.29 (broad,

[0070] 4H),2.43(s,3H),2.33(s,3H),2.21(m,2H),1.91(m,2H),1.79(m,2H),1.59(m,2H); 13C NMR (150MHz, DMSO-d6 / TFA): δ

[0071] 202.4,160.7,154.8,158.3,158.0,144.9,142.3,142.0,134.6,129.7,126.7,115.3,107.0,53.0,45.6,42.6,31.3,27.6,25.2,13.7.

[0072]

[0073] Embodiment 2-7

[0074] Example 2-8 is the same as Example 1, except that the catalyst used in the synthesis of 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one is different.

[0075] Example 2, 4 ml of concentrated sulfuric acid, 1 ml of benzothiazole hydrogen sulfate. The yield of the prepared 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one was 94%.

[0076] Example 3, concentrated sulfuric acid 4.5 ml, benzothiazole hydrogen sulfate 0.5 ml. The yield of the prepared 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one was 91%.

[0077] Example 4, benzothiazole hydrogen sulfate 5 ml. The yield of the prepared 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one was 48%.

[0078] Example 5, concentrated sulfuric acid 4.8 ml, benzothiazole hydrogen sulfate 0.2 ml. The yield of the prepared 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one was 70%.

[0079] Example 6, concentrated sulfuric acid 3 ml, benzothiazole hydrogen sulfate 2 ml. The yield of the prepared 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one was 65%.

[0080] Example 7, concentrated sulfuric acid 2 ml, benzothiazole hydrogen sulfate 3 ml. The yield of the prepared 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one was 52%.

[0081] Although the specific embodiments of the present disclosure are described above, it should be understood by those skilled in the art that these are only examples, and the protection scope of the present disclosure is defined by the appended claims. Those skilled in the art may make various changes or modifications to these embodiments without departing from the principles and essence of the present disclosure, but these changes and modifications all fall within the protection scope of the present disclosure.

Claims

1. A method for preparing a palbociclib intermediate, characterized in that: The palbociclib intermediate is 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one; the method comprises the following steps: Using 2,4-dichloropyrimidine as a starting material, a cyclopentylamine group is introduced through amination with cyclopentylamine to obtain 2-chloro-4-cyclopentylaminopyrimidine; 2-Chloro-4-cyclopentylaminopyrimidine reacts with β-ketoacetate at 180°C under acidic conditions to give 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one; The acidic conditions are obtained by adding 98% concentrated sulfuric acid and benzothiazole ionic liquid; The benzothiazole ionic liquid is selected from one or more of benzothiazole hydrogen sulfate, benzothiazole perchlorate, and benzothiazole nitrate; The mass ratio of the 98% concentrated sulfuric acid to the benzothiazole ionic liquid is 1:0.1-0.

3.

2. A method for preparing Palbociclib, characterized in that: The following steps are involved: Using 2,4-dichloropyrimidine as a starting material, a cyclopentylamine group is introduced through amination with cyclopentylamine to obtain 2-chloro-4-cyclopentylaminopyrimidine; 2-Chloro-4-cyclopentylaminopyrimidine reacts with β-ketoacetate at 180°C under acidic conditions to give 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one; The acidic conditions are obtained by adding 98% concentrated sulfuric acid and benzothiazole ionic liquid; The benzothiazole ionic liquid is selected from one or more of benzothiazole hydrogen sulfate, benzothiazole perchlorate, and benzothiazole nitrate; The mass ratio of the 98% concentrated sulfuric acid to the benzothiazole ionic liquid is 1:0.1-0.3; The 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one is subjected to a bromination reaction to obtain an intermediate A; ; The intermediate B 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester reacts with the intermediate A in the presence of isopropylmagnesium chloride to prepare the intermediate C; ; Intermediate C is reacted with butyl vinyl ether in the presence of a platinum catalyst to obtain intermediate D; ; The intermediate D is hydrolyzed and deprotected under acidic conditions to obtain palbociclib; 。